You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

166 Results
Regimen
Cancer Type:
Sarcoma, 
Giant Cell Tumour
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
denosumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC), based on criteria
Exceptional Access Program
    osimertinib - For the treatment of locally advanced, unresectable (stage III) non-squamous non-small cell lung cancer (NSCLC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
blinatumomab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Endocrine, 
Pancreatic Neuroendocrine, 
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    Belzutifan – For the treatment of adult patients with von Hippel-Lindau (VHL) disease, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
belzutifan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Cetuximab and Radiation - Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cetuximab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daSATinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
CISplatin,
cytarabine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
durvalumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
Exceptional Access Program
    enzalutamide - For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enzalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Skin, 
Basal Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vismodegib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023

Pages